Breakthrough Lassa Fever Vaccine Shows Promise in First Human Trial

What's New in Lassa Fever Vaccine Development?

IAVI's Lassa fever vaccine candidate demonstrated favorable safety and robust immune responses in its first human trial, marking a significant milestone in addressing this viral hemorrhagic fever that threatens millions across West Africa. The recombinant vesicular stomatitis virus (rVSV)-based vaccine, developed through a consortium led by the International AIDS Vaccine Initiative (IAVI), successfully completed a Phase 1 study in both U.S. and Liberian adults, with no vaccine-related serious adverse events reported.

The randomized, double-blind, placebo-controlled trial evaluated rVSVΔG-LASV-GPC, a vaccine candidate constructed using the same platform technology as Merck's FDA and EMA-approved Ebola vaccine ERVEBO. The study enrolled 53 U.S. and 60 Liberian participants across multiple dose cohorts ranging from 2×10⁴ to 2×10⁷ plaque-forming units (PFU). The vaccine's design, which replaces the VSV envelope glycoprotein with Lassa virus glycoprotein complex, builds upon preclinical studies that demonstrated 100% protection in non-human primates against lethal Lassa virus challenge. This approach leverages the established safety profile of the rVSV platform, which has been administered to over 300,000 people during Ebola outbreaks since 2016. The trial's progression from U.S. dose-escalation cohorts to Liberian expansion cohorts represents a strategic advancement toward potential deployment in endemic regions where Lassa fever causes thousands of infections annually with case fatality rates between 15-20% in hospitalized patients. No vaccines are currently approved for Lassa fever, which has been identified by the WHO as a priority pathogen with pandemic potential requiring urgent research attention.

Is the Vaccine Meeting Safety and Efficacy Expectations?

The vaccine induced robust antibody responses in nearly all recipients (97.7% of U.S. and 91.7% of Liberian vaccinees), typically detectable by day 29 post-vaccination and peaking around day 85. Importantly, these responses demonstrated cross-reactivity against multiple Lassa virus lineages, including lineages predominant in Nigeria where recent outbreaks have occurred. Neutralizing antibody responses were observed in 97.7% of U.S. and 75.0% of Liberian vaccine recipients, with persistence through one year of follow-up. The vaccine also elicited strong T-cell responses, considered critical for viral clearance, in all U.S. participants with available samples. Notably, the study found that a second dose provided no appreciable enhancement of immune responses, suggesting a single-dose regimen may be sufficient. This characteristic could significantly facilitate deployment in resource-limited settings where logistical challenges often complicate multi-dose vaccination campaigns. The immunogenicity profile appeared consistent across the tested dose range, though reactogenicity was dose-dependent, with mild-to-moderate local and systemic reactions more common at higher doses. U.S. participants reported more reactogenicity events than Liberian participants, potentially reflecting different reporting patterns or environmental factors influencing vaccine responses.

Safety monitoring revealed no vaccine-related serious adverse events or adverse events of special interest, including no cases of hearing loss—a known complication of Lassa fever infection. Transient detection of vector-derived RNA in plasma and saliva samples was observed, consistent with findings from studies of the related ERVEBO vaccine, though no infectious vaccine virus was recovered from any samples. The most common adverse events included tenderness at the injection site, malaise, headache, myalgia, and chills, with higher-grade events primarily occurring at the highest dose level (2×10⁷ PFU). Symptoms typically resolved within days without intervention. One participant experienced transient liver enzyme elevation, a phenomenon also reported in previous ERVEBO studies. The comprehensive safety evaluation included specialized audiometry assessments, given Lassa fever's association with sensorineural hearing loss. "The favorable safety profile and robust immunogenicity observed in this first-in-human trial provide a strong foundation for advancing this vaccine candidate," noted the investigators in their report published in the New England Journal of Medicine.

What Are the Implications for Global Health Security?

The study's findings have significant implications for global health security and pandemic preparedness strategies. Lassa fever, which causes approximately 300,000 infections annually with up to 5,000 deaths, has demonstrated increasing geographic spread beyond its traditional endemic regions in Sierra Leone, Liberia, Guinea, and Nigeria. Recent cases of international importation to Europe and the United States underscore the virus's potential for wider dissemination. The development of an effective vaccine represents a critical countermeasure against both endemic transmission and potential pandemic threat. Based on these promising Phase 1 results, follow-up Phase 2/3 clinical studies have been initiated (ClinicalTrials.gov NCT05868733) to confirm these findings in larger populations, expand the safety database, and assess efficacy in LASV-exposed individuals. The advancement of this vaccine candidate exemplifies the growing capability of the biomedical research community to respond to emerging infectious disease threats using platform technologies with established regulatory precedents.

The study also examined whether environmental factors might contribute to differential antibody responses between U.S. and Liberian cohorts. Pre-existing immunity was detected in some Liberian participants, with four participants showing pre-existing LASV NP IgG antibodies, potentially related to past LASV exposure or cross-reactivity to glycoproteins from other arenaviruses. This finding warrants further investigation into vaccine responses in previously exposed individuals living in endemic regions. Study limitations included the relatively small sample size, loss of some U.S. participants to follow-up, and the presence of pre-existing antibodies in some Liberian participants, all factors that the planned Phase 2/3 studies aim to address.

How Does This Innovation Compare with Industry Trends?

Industry Context: The progression of IAVI's Lassa fever vaccine represents a significant advancement in the expanding field of emerging infectious disease countermeasures. This development parallels broader industry trends toward leveraging established vaccine platforms like rVSV for rapid response to priority pathogens. The success of this approach follows similar strategies employed for other hemorrhagic fevers, most notably Ebola, where vector-based vaccines have demonstrated clinical success. This work exemplifies how public-private partnerships involving research institutions, biotech organizations, and international health agencies can effectively advance vaccines for diseases that primarily affect low-resource regions—historically underserved by commercial pharmaceutical development. As global health security concerns continue to drive investment in pandemic preparedness, such vaccine candidates address both regional endemic disease burdens and international biosecurity priorities.

Summary

IAVI's Lassa fever vaccine candidate has successfully completed its first human trial, demonstrating excellent safety and strong immune responses in both U.S. and Liberian participants. The Phase 1 study of the rVSVΔG-LASV-GPC vaccine enrolled 113 adults across multiple dose cohorts and reported no vaccine-related serious adverse events. The vaccine induced robust antibody responses in over 90% of recipients, with neutralizing antibodies detected in 97.7% of U.S. and 75.0% of Liberian participants that persisted through one year of follow-up. Importantly, these responses showed cross-reactivity against multiple Lassa virus lineages. The vaccine also elicited strong T-cell responses and appears to require only a single dose for effectiveness, which would simplify deployment in resource-limited endemic regions. Built on the same rVSV platform as the FDA-approved Ebola vaccine ERVEBO, this candidate addresses a critical unmet need for Lassa fever, which causes approximately 300,000 infections and up to 5,000 deaths annually in West Africa. The WHO has identified Lassa fever as a priority pathogen with pandemic potential, and no vaccines are currently approved for this viral hemorrhagic fever. Based on these promising results, Phase 2/3 clinical studies have been initiated to confirm findings in larger populations and assess efficacy in virus-exposed individuals, representing a significant milestone in global health security and pandemic preparedness efforts.